Search PubMed⌕ Search

Biomedical subjects

A Stoudemire

Publications and source records attributed to A Stoudemire.

At least 73 records · Page 4Linked to original sources
PubMed1986

Recent research developments in consultation-liaison psychiatry.

With the major changes in health care and general hospital practice in the last decade, practice and research in consultation and liaison psychiatry have also changed dramatically. The authors present a selected review of recent advances and implications for five important topics in consultation-liaison research: diagnosis, disease mechanisms, biologic treatments, health services, and psychosocial treatments for medical disorders.

Disease↗
PubMed1986

Metoclopramide-induced tardive dyskinesia: a case report.

A case of tardive dyskinesia developed in a patient who had been treated with metoclopramide for 8 months. Acute extrapyramidal side effects are also possible with this medication. Guidelines for the use of metoclopramide are presented with special emphasis on patients with renal insufficiency and the elderly. The importance of consultation-liaison psychiatrists' familiarity with the neurologic side effects of this commonly prescribed drug used in general medical practice is emphasized.

Aged↗
PubMed1985

Contrasting models for combined medical and psychiatric inpatient treatment.

The authors contrast the clinical, administrative, and reimbursement aspects of two units offering combined medical and psychiatric inpatient treatment, one under medical auspices (the medical/psychiatric model), the other under psychiatric auspices (the psychiatric/medical model). The typical patient on both units suffered from depression with prominent somatic symptoms. The psychiatric/medical model was clinically advantageous because of its greater capacity for containing agitated, psychotic, and suicidal behavior and because of its potentially longer lengths of stay for refractory patients. Furthermore, the psychiatric/medical model offers more predictable payment for psychotherapy under fee-for-service insurance and is less likely to be adversely affected by the current prospective payment system based on diagnosis-related groups.

Depressive Disorder↗
PubMed1984

Development of an organic affective syndrome during a hyperbaric diving experiment.

The authors describe the clinical and pharmacologic management of a patient who developed an organic affective syndrome during a simulated deep-diving experiment. The physiological complexities of deep-diving research are reviewed, as well as the neuropsychiatric symptoms of the high pressure nervous syndrome.

Atmosphere Exposure Chambers↗
PubMed1984

Neuroleptic malignant syndrome and neuroleptic-induced catatonia: differential diagnosis and treatment.

The clinical manifestations, differential diagnosis, and treatment of the neuroleptic malignant syndrome and neuroleptic-induced catatonia are discussed. A case is presented in which the catatonic-like behavior and extrapyramidal sequelae of the neuroleptic malignant syndrome responded to combined treatment with anticholinergics and levodopa/carbidopa. Differential diagnosis and theories regarding the development of these neuroleptic-induced disorders are reviewed.

Aged↗
PubMed1984

Recent advances in the pharmacologic and behavioral management of chemotherapy-induced emesis.

Chemotherapy protocols that induce severe protracted nausea and vomiting are stressful for cancer patients, and the fear that may be associated with chemotherapy often outweighs other negative aspects of the cancer experience. The clinical management of chemotherapy-induced emesis involves pharmacologic approaches, maintenance of hydration, provision of emotional support, and the possible use of behavioral relaxation techniques. We review the literature on the psychological side effects of chemotherapy and offer recommendations for the pharmacologic, supportive, and behavioral treatment of chemotherapy-induced emesis. More effective management of chemotherapy-induced nausea and vomiting also enhances patient compliance and therefore potentially decreases overall morbidity and mortality.

Antiemetics↗
PubMed1984

Propranolol and depression: a reevaluation based on a pilot clinical trial.

A wide range of neuropsychiatric side effects are attributed to propranolol including visual hallucinations, somnulence, memory impairment, decrease in response time, dizziness, confusional states, insomnia, nightmares, fatigue, sedation and depression. Benson et al., in a summary review of several clinical studies of 5,846 patients being treated with a variety of beta adrenergic blocking agents, listed depression as a rare side effect of propranolol that was usually reported only after long term treatment at high doses. Despite the widely circulated attribution that depression is a side effect of propranolol, there is a paucity of evidence to directly link this drug with clinically significant mood disturbance. For example, the most widely quoted reference attributing propranolol as a depressogenic agent was a "letter to the editor" which was a retrospective, uncontrolled, unblinded study that did not use a standardized depression rating scale. Most of the evidence linking propranolol to depressive symptoms have derived from scattered case reports in which the onset of depressive symptoms were attributed to this agent. Given the well known cyclic onset and remissions of affective disorders, and the prevalence of depression in the general medical population as a whole, the role of propranolol in these cases is debatable.

Aged↗
PubMed1983

Medication noncompliance: systematic approaches to evaluation and intervention.

Medication noncompliance is a significant problem in medical practice, but many intervention strategies developed for noncompliant patients (such as tangible rewards, contingency contracting) are not practical for the large numbers of patients seen by private practitioners on an ongoing basis. Based upon a review of the literature concerning the key determinants affecting compliance, the authors have developed a practical, rational, and systematic approach to assessing medication compliance that may serve as a guide for psychiatrists in formulating consultation recommendations, in liaison teaching activities, and in clinical psychiatric practice. Special emphasis is placed upon the identification of psychiatric syndromes that may negatively affect compliance. Implications for compliance-related research in consultation-liaison psychiatry are also discussed.

Defense Mechanisms↗
PubMed1983

Central nervous system sarcoidosis.

Sarcoidosis may involve the central nervous system (CNS) in approximately 5% of cases. Three levels of neurological involvement are possible and include cranial nerve abnormalities, peripheral neuropathies, and lesions of the brain, spinal cord, and meninges. In addition to abnormal neurological findings, psychiatric presentations of CNS sarcoidosis include symptoms of delirium, dementia, depression, personality changes, and psychosis. The diagnosis usually rests on neurological, psychiatry, and cerebrospinal fluid (CSF) abnormalities with a history of sarcoidosis in other organ systems. The CSF, however, may be normal in as many as 30% of cases. The complexities of the illness and the difficulties that may be encountered in making the diagnosis are illustrated with a case of suspected CNS sarcoidosis that presented with delirium and choreoathetosis. The use of steroids as the mainstay of treatment is also discussed.

Central Nervous System Diseases↗